Skip to main content
SpringerLink
Log in

Pulmonal arterielle Hypertonie (PAH)

Kein Vorteil durch initiale Triple- versus duale Therapie bei inzidenter PAH

  • Journalclub
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Galié N, Humbert M, Vachiery JL et al. 2015 ERS/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015;46:903-75

  2. Sitbon O, Channick R, Chin K et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-33

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik u. Poliklinik II - Sektion Pneumologie, Universitätsklinikum Bonn, Venusberg-Campus 1, 53127, Bonn, Deutschland

    Dirk Skowasch

Authors
  1. Dirk Skowasch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Skowasch.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Skowasch, D. Kein Vorteil durch initiale Triple- versus duale Therapie bei inzidenter PAH. Pneumo News 13, 20–21 (2021). https://doi.org/10.1007/s15033-021-2786-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-021-2786-9

Search

Navigation